N@N

InterMune Inc (NASDAQ:ITMN), Down By 11.47% ($1.03) From $8.980 After BUYINS.NET Report Predicted Weakness After Earnings

November 8, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, November 6th 2012 stating that InterMune Inc (NASDAQ:ITMN) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=itmn&id=325236

At the time this story was written, InterMune Inc (NASDAQ:ITMN) is Down By 11.47% ($1.03) From $8.980 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

InterMune Inc (NASDAQ:ITMN) - InterMune, Inc., a biotech company, focuses on developing and commercializing therapies in pulmonology and hepatology primarily in the United States and Europe. The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease. Its pulmonology product portfolio includes lead product candidate, pirfenidone, a phase III product being developed for the treatment of patients with idiopathic pulmonary fibrosis; and a research program focused on small molecules for pulmonary diseases. The companys hepatology portfolio comprises the HCV protease inhibitor RG7227, a phase IIb chronic hepatitis C program and an early stage research program evaluating a new target in hepatology. It has license and collaboration agreements with Genentech, Inc.; Boehringer Ingelheim International GmbH; Connetics Corporation; and Novartis Corporation. The company was founded in 1998 and is headquartered in Brisbane, California..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InterMune Inc (NASDAQ:ITMN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---